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Deep brain stimulation targeting the subthalamic nucleus (STN-DBS) is an effective
surgical treatment for the motor symptoms of Parkinson’s disease (PD), the precise
neuronal mechanisms of which both at molecular and network levels remain a topic of
debate. Here we employ two transgenic mouse lines, combining translating ribosomal
affinity purification (TRAP) with bacterial artificial chromosome expression (Bac), to
selectively identify changes in translational gene expression in either Drd1a-expressing
striatonigral or Drd2-expressing striatopallidal medium spiny neurons (MSNs) of the
striatum following STN-DBS. 6-hydroxydopamine lesioned mice received either 5 days
stimulation via a DBS electrode implanted in the ipsilateral STN or 5 days sham treatment
(no stimulation). Striatal polyribosomal RNA was selectively purified from either Drd2 or
Drd1a MSNs using the TRAP method and gene expression profiling performed. We
identified eight significantly altered genes in Drd2 MSNs (Vps33b, Ppp1r3c, Mapk4,
Sorcs2, Neto1, Abca1, Penk1, and Gapdh) and two overlapping genes in Drd1a
MSNs (Penk1 and Ppp1r3c) implicated in the molecular mechanisms of STN-DBS.
A detailed functional analysis, using a further 728 probes implicated in STN-DBS,
suggested an increased ability to receive excitation (mediated by increased dendritic
spines, increased calcium influx and enhanced excitatory post synaptic potentials)
accompanied by processes that would hamper the initiation of action potentials,
transport of neurotransmitters from soma to axon terminals and vesicular release in
Drd2-expressing MSNs. Finally, changes in expression of several genes involved in
apoptosis as well as cholesterol and fatty acid metabolism were also identified. This
increased understanding of the molecular mechanisms induced by STN-DBS may reveal
novel targets for future non-surgical therapies for PD.
Keywords: Parkinson’s disease, deep brain stimulation, subthalamic nucleus, striatal medium spiny neurons,
translational profile
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative disease
characterized by bradykinesia, akinesia, rigidity, and tremor at
rest (Lang and Lozano, 1998). It is well established that loss
of midbrain dopaminergic neurons in the substantia nigra pars
compacta (SNc) is the key pathology underlying the motor
deficits of the disease (Forno, 1996). The striatum is the most
prominent recipient of these dopaminergic projections and is
known to play a key role in mediating the clinical symptoms
of PD. The classical model of PD pathophysiology exploits
the opposing effects of dopamine on striatopallidal (Drd2) and
striatonigral (Drd1a) medium spiny neurons (MSNs) to explain
the clinical features of bradykinesia, rigidity, and akinesia (Albin
et al., 1989). Thismodel suggests that the loss of striatal dopamine
causes an imbalance between the activity of Drd1a and Drd2
populations leading to abnormal activity in recipient neurons in
the pallidum and substantia nigra pars reticulata (SNr) leading
to abnormal activity in downstream thalamo-cortico-thalamic
activity.
Deep brain stimulation targeting the subthalamic nucleus
(STN-DBS) is a well-established, increasingly common, surgical
treatment to alleviate the motor symptoms of PD. Three of
the four cardinal features of PD, rigidity, bradykinesia and rest
tremor, are consistently improved by STN-DBS. The magnitude
of benefit has been estimated to be ∼80% for tremor, and
∼40–60% for rigidity, and bradykinesia (Fasano et al., 2012).
Furthermore, a ∼50% reduction in the dose of dopaminergic
medications is feasible post STN-DBS, thereby improving the
incidence of dyskinesias (Fasano et al., 2012). The mechanisms
through which STN-DBS reduces PD symptoms are a matter of
dispute. However, it is clear that STN-DBS results in significant
changes in the activity of the entire subthalamo-pallidal loop as
well as antidromic effects targeting upstream structures such as
cerebral cortex (Li et al., 2007; Hammond et al., 2008). Although
a very effective treatment strategy for PD, there are several
limitations that drive the search for alternative therapies to STN-
DBS. There are obvious risks associated with installing electrodes
in the brain. Moreover, levodopa-resistant axial signs, cognitive
dysfunction and severe mood or psychiatric disorders can worsen
in some individuals following STN-DBS (Follett, 2004; Fasano
et al., 2012, 2015). A better understanding of the molecular
mechanisms induced by STN-DBS may reveal novel targets for
future non-surgical therapies able to selectively reduce the motor
symptoms of PD.
Although the striatum is the main input structure of the
basal ganglia, receiving substantial input from the cerebral cortex,
thalamus and midbrain dopaminergic neurons, and the hallmark
symptoms of PD have been explained as an imbalance between
Drd2 and Drd1a activity, these striatal neurons are absent from
current models explaining the mechanisms of therapeutic effects
in STN-DBS (Kopell et al., 2006; Montgomery and Gale, 2008).
Here we use microarray technology to describe gene expression
changes in both Drd2 and Drd1a MSNs following STN-DBS
in a mouse model of PD. Using two BacTRAP transgenic
mice expressing GFP under the expressional control of Drd1a
and Drd2 dopamine receptor promotors, we are able to detect
changes caused by STN-DBS in Drd1a and Drd2 populations
separately (Heiman et al., 2008). We demonstrate significant
changes in the expression of several genes in Drd2 MSNs
with weaker involvement of the Drd1a population following
STN-DBS. Our data provide novel insight into the effects of
STN-DBS on multiple molecular signaling pathways in striatal
MSNs potentially revealing novel targets for development of new
therapies targeted at treating the motor symptoms of PD and
harnessing the success of STN-DBS by a non-surgical means.
Materials and Methods
BacTRAP Mice
The use of all animals adhered to the humane standards set by
the Canadian Council on Animal Care (CCAC). In addition, all
experimental procedures have already undergone peer review for
scientific merit and a requisite Animal Use Protocol has been
approved by the Animal Care Committees at the University
of Toronto and Centre for Addiction and Mental Health. The
number of animals in each group was restricted to three for
humane reasons as the experimental intervention (stereotaxic
lesion of the nigrostriatal pathway, followed by stereotaxic
implantation of a STN-DBS electrode), was very invasive.
Two Bac transgenic mouse lines were obtained from the
Rockefeller Institute. Both lines expressed an EGFP-L10a fusion
protein under the control of the dopamine receptor Drd1a (line
CP73) or Drd2 (line CP101) promoter. For a full description of
the mice please refer to (Doyle et al., 2008; Heiman et al., 2008).
Both lines were on a C57BL/6J/Swiss-Webster background and
were maintained as transheterozygous.
6-OHDA Lesion of the Median Forebrain Bundle
Six Drd1a and six Drd2 BacTRAP mice were rendered
parkinsonian using the neurotoxin 6-OHDA to create a lesion
of the nigrostriatal pathway (Cenci and Lundblad, 2007). All
animals were lesioned at 35 days of age. Thirty minute prior to
lesioning animals received desipramine (25mg/kg) and pargyline
(5mg/kg) i.p (Both Sigma Aldrich). Briefly, under general
anesthesia, 6-OHDA (3µg in 0.6µl) (Sigma Aldrich) was infused
unilaterally into the medial forebrain bundle (MFB) at a flow rate
of 0.2µl/min at the following coordinates fromBregma: AP−1.2,
ML −1.1, DV −5.0mm according to the atlas of Paxinos and
Franklin (2004). Post-surgery, animals were allowed to recover
for a period of 14 days.
STN DBS Electrode Implant
Fourteen days post-6-OHDA lesion, all 6-OHDA-lesioned Drd1a
and Drd2 BacTRAP mice were unilaterally implanted with
STN electrodes in the same hemisphere as the 6-OHDA
lesion as described below. Animals were anesthetized with
ketamine/xylazine (75/10mg/kg i.p.) and had their heads fixed
to a stereotactic frame. Electrodes with 0.125µm diameter were
connected to a plastic pedestal (Plastics One) and unilaterally
implanted in the STN (at the following coordinates from Bregma
AP: −1.70mm, ML: 1.52mm and from dura DV: −4.5mm
according to the atlas of Paxinos and Franklin (2004) and used as
cathodes A screw implanted over the somatosensory cortex was
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used as the anode. Two additional screws were attached to the
skull for better securing the cap in place. Electrodes and screws
were fixed to the skull with dental acrylic cement. Supplemental
Figure 1 illustrates the location of the electrode tip within the
STN.
Deep Brain Stimulation Protocol
Stimulation was conducted with a handheld stimulator (ANS
model 3510) at 100µA, 130Hz, and 90µs for 4 h/day for 5
consecutive days. This current was chosen as, based on the
configuration of our electrodes, it generates a charge density
comparable to that used in patients with DBS electrodes and
should therefore be in a safe range not to create a lesion (Hamani
et al., 2010; Hamani andNobrega, 2012). The selected pulse width
and frequency are similar to those used in clinical practice. Sham
treated parkinsonian animals had electrodes implanted in the
STN but did not receive stimulation.
Post-mortem Verification of Lesion Efficiency
Post mortem, lesion efficiency was assessed by calculating nigral
tyrosine hydroxylase (TH) immunoreactive cell loss. Animals
were euthanized immediately the stimulator was turned off
following 5 consecutive days of stimulation. The brain was
removed and dissected. The midbrain, including SNc was
immersion fixed in 4% paraformaldehyde. Following fixation in
4% paraformaldehyde, blocks encompassing the entire midbrain
were paraffin embedded and 5µ-thick serial sections taken
from −3.08 and −3.28mm relative to Bregma according to
the atlas of Franklin and Paxinos (2007). Briefly, endogenous
peroxidase was blocked with 3% hydrogen peroxide, antigen
retrieval was with 10mM citrate buffer at pH 6.0 and sections
were stained overnight with rabbit polyclonal antibody to TH
(Novus Biologicals) at 1/1500 dilution. Staining was finished
with Vector’s Peroxidase ImmPRESS detection system, color
developed byDAB and sections were counterstained withMayer’s
hematoxylin prior to coverslipping. TH positive cells were
defined as those with a brown cell membrane with distinct lighter
rounded cell body. All animals included in the study had a >90%
loss of TH immunoreactive cells in the lesioned hemisphere as
compared to the intact hemisphere (data not shown).
Translating Ribosomal Affinity Purification (TRAP)
The rostral portion of the brain, including striatum, was
dissected and translational polyribosomal RNA was isolated
from the lesioned hemisphere via the TRAP technique using
the polysome purification protocol provided by BacTRAP.org
(http://www.bactrap.org/downloads/Polysome_IP_Protocol.pdf).
All steps were carried out under RNAse free conditions. Dissected
striata were individually homogenized, using a motor driven
teflon-glass homogenizer, in ice cold lysis buffer (20mM HEPES
KOH, 5mM MgCl2, 150mM KCL, 0.5mM DTT, 100µg
cyclohexaminde, 40U/ml Rnasin and protease inhibitor cocktail,
pH 7.4). The homogenates were then centrifuged at 2000× g
for 10min at 4◦C. Homogenates were then mixed in NP-40,
final concentration of 1%, and 1,2-diheptanoyl-sn-glycero-3-
phosphocholine (DHPD, Avanti Polar Lipids, Alabaster, AL),
final concentration of 30mM for 5min before centrifugation
at 20,000 × g for 10min at 4◦C. Homogenates were then
immunoprecipitated for 30min at 4◦Cwith end-over-endmixing
with 200µl freshly-prepared antibody-bound beads [50µg each
of anti-GFP antibodies (clone 19C8 and 19F7, Memorial
Sloan-Kettering Monoclonal Antibody Facility) were bound to
Dynal (protein G magnetic beads, Invitrogen, Carlsbad, CA)
by incubation with slow end-over-end mixing for 1 h at room
temperature]. Following incubation, beads were collected using
a magnetic rack then washed four times in ice cold wash buffer
20mMHEPES-KOH, 5mMMgCl2, 350mM KCL, 0.5mMDTT,
1% NP-40, 100µg cyclohexaminde, pH 7.4. After the last wash,
RNA was eluted from the beads according the manufacturer’s
instructions using an Absolutely RNA nanoprep kit (Stratagene,
La Jolla, CA) with in column DNA digestion. RNA quantity
was determined using a Nanodrop 1000 spectrophotometer
(Wilmington, DE).
Microarray
RNA quality and integrity were assessed using a bioanalyzer
2100 (Agilent) prior to microarray. For microarray 1 ng of
each sample was amplified (Nugen) and labeled using Illumina
totalprep 96-rna amplification kit (Ambion). 1.5µg of cRNA of
each sample generated from the amplification kit was hybridized
into one mouse wg-6 v2.0 beadchip (Illumina). The beadchip
was incubated at 58◦C rotating for 18 h for hybridization.
The beadchip was then washed and stained as per Illumina
protocol and scanned on the iscan (Illumina). Data files were
quality control tested and quantified in genomestudio version
2010.1 (Illumina). Data was analyzed using Genespring and
r/Bioconductor software.
Data Analysis
Data was imported in GeneSpring v12.1 for analysis. During
import, the data was normalized using a standard (for Illumina
arrays) quantile normalization followed by a “per probe” median
centered normalization. All data analysis and visualization were
performed on log2 transformed data. This study comprised 4
experimental groups (Drd1a sham, Drd1a STN-DBS, Drd2 sham,
and Drd2 STN-DBS). A total of 45281 probes are represented on
the Mouse WG-6V2 BeadChip. Data was first filtered to remove
the confounding effect probes that show no signal may have on
subsequent analysis. Only probes that were above the twentieth
percentile of the distribution of intensities in 100% of any of
the one of four above groups were allowed to pass through this
filtering. The final set contained 37,650 probes. An unsupervised
clustering using a Pearson centered correlation as a distance
metric with average linkage rules in the tree building algorithm
of this set of probes demonstrated a reasonable, but not perfect,
separation between the samples into the experimental groupings
(Figure 1).
Quantitative Real Time Polymerase Chain
Reaction
Microarray data were validated using real time quantitative
real time polymerase chain reaction (qRT-PCR) of selected
transcripts showing a differential expression in DBS and Sham
animals. Primer pairs were designed using Primer3 software
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FIGURE 1 | Heat-maps of supervised clusters of gene expression
changes in Drd1a and Drd2 expressing MSNs following STN-DBS.
Probes consistently altered in correlation are clustered together. (A) A
magnification of the clustering results showing altered genes (rows) by
sample (columns). The dendogram on top illustrates the similarity of
samples within each group, whereas the dendogram to the left shows the
hierarchical clustering based on similarity between the expression of
genes. (B) Heat map illustrating array-wide gene expression between the
four experimental groups. A clear separation in the gene expression
between Drd1a and Drd2 expressing MSNs is apparent as well as
changes in expression of several genes following STN-DBS. Changes in
gene expression following STN-DBS are best observed in Drd2 MSNs.
Except for genes on the top of the figure, expression of most genes
remain almost unchanged in Drd1a MSNs.
(http://bioinfo.ut.ee/primer3/). 2µ g of total RNA sample were
reverse transcribed using Superscript III reverse transcriptase
(Invitrogen) and the diluted cDNA (equivalent to 100 ng of total
RNA) underwent qRT-PCR in triplicate using SYBR Premix
Ex Taq (Perfect Real Time) (TaKaRa) and 7500 Realtime PCR
System (Applied Biosystems) according to the manufacturers’
instructions. In all cases β-Actin (Actb) served as an internal
control.
Results
This pilot study included animals in four experimental groups.
All animals had a 6-OHDA lesion of the median forebrain
bundle. The sample groups comprised of Drd1a mice receiving
STN-DBS, Drd1a mice implanted without stimulation (sham),
Drd2 mice receiving STN-DBS and Drd2 sham mice (see
Materials and Methods). We performed two One-Way ANOVA
tests with Benjamini-Hochberg False Discovery Rates of p < 0.1
(corrected) and p < 0.01 (uncorrected) between all sample
groups. These tests yielded 16 and 728 significantly varying
probes listed in Supplementary Tables 1 and 2, respectively.
The uncorrected probes were clustered to reveal genes altered
similarly (Figure 1). The two right columns of Figure 1B show
that expressions of many Drd2 MSN genes have changed due
to STN-DBS. In comparison, expressions of much fewer Drd1a
genes change following DBS (the two left columns in Figure 1B).
The 728 genes from the uncorrected One-Way ANOVA
were next filtered to remove genes with a <1.5 fold change.
Out of 728 uncorrected genes, expression of only 291 genes
altered greater than 1.5 folds in at least one of the four
comparisons. Interestingly, expression of 102 genes changed
specifically in Drd1a MSNs while expression of only 56 genes
altered in Drd2 MSNs following STN-DBS. Expression of 14
genes shared between Drd1a and Drd2 genes changed following
the stimulation.
We are specifically interested in two major pairwise
comparisons: genes altered in Drd1a (Drd1a sham vs. Drd1a
stim.) and Drd2 (Drd2 sham vs. Drd2 stim.) MSNs following
STN-DBS. Two minor comparisons i.e., genes differentially
expressed between Drd1a and Drd2 MSNs before (Drd1a sham
vs. Drd2 sham) and after (Drd1a stim. vs. Drd2 stim.) stimulation
are also reported to add to the prior knowledge about genetic
differences between Drd1a and Drd2 MSNs in health and disease
(Heiman et al., 2008, 2014; Visanji et al., 2012; Visanji et al.,
submitted).
To perform specific pairwise comparisons of interest, we
applied a post-hoc Tukey’s honest significant difference test
(THSD) to the 291 uncorrected filtered genes. Finally a Two-
Way ANOVA (uncorrected) was also performed with MSN
type (Drd1a or Drd2) and treatment (STN-DBS or sham)
as the factors (Supplementary Tables 3, 4). Supplementary
Tables 5, 6 list genes involved in the two major pairwise
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comparisons while Supplementary Tables 7, 8 list those of the
two minor comparisons. Each of Supplementary Tables 5–8
contains four sublists of genes, each representing the results of
corresponding statistical tests performed in order of stringency:
One-Way ANOVA (corrected), One-Way ANOVA (uncorrected
passing post-hoc THSD), Two-Way ANOVA (uncorrected) and
uncorrected results failing THSD (listed in black, blue, red, and
green, respectively).
Venn diagrams were used to demonstrate which gene
expression changes were common to and exclusive to each of
the different experimental conditions. Figure 2A demonstrates
that out of 285 and 197 genes altered after STN-DBS in Drd2
and Drd1 MSNs respectively, 102 genes are shared. 183 genes
exclusively alter in Drd2 MSNs, and 95 genes alter exclusively in
Drd1a MSNs. This observation suggests that the major influence
of STN-DBS on striatal MSNs is exerted on Drd2MSNs with only
minor involvement of the Drd1a population. This pattern is also
evident when considering the corrected genes alone (Figure 2B),
FIGURE 2 | Overlap of differentially expressed genes in the direct and
indirect pathways following STN-DBS in a mouse model of PD. (A)
Uncorrected (B) Corrected. All genes underwent a filtering process to remove
those exhibiting <1.5 fold change. Drd1a Sham vs. stim: Genes altered in
Drd1a MSNs before and after STN-DBS. Drd2 sham vs. stim: Genes altered in
Drd2 MSNs before and after STN-DBS. Sham Drd1a vs. Drd2: Genes
differentially expressed between Drd1a and Drd2 MSN before STN-DBS. Stim
Drd1a vs. Drd2: Genes differentially expressed between Drd1a and Drd2 MSN
after STN-DBS.
thus following STN-DBS there are eight significantly altered
corrected genes in Drd2 MSNs with two of these genes also
significantly altered in Drd1a MSNs.
Functional Analysis
The eight corrected genes exhibiting a >1.5 fold change in
Drd2 MSNs after STN-DBS (Vps33b, Ppp1r3c, Mapk4, Sorcs2,
Neto1, Abca1, Penk1, andGapdh) and two overlapping candidate
genes in Drd1a MSNs (Penk1 and Ppp1r3c) were used as
backbones for functional analysis to create a framework to
exploit uncorrected results of changes in Drd1a and Drd2 MSNs
following STN-DBS (Table 1). Thus, eight functional clusters
were generated by assigning each uncorrected gene to one of
the functions defined by corrected genes. The first functional
cluster, built upon a significant change (corrected) in Ppp1r3,
Neto1, and Sorcs2 contains 22 genes and describes genes related
to dendritic excitability (Supplementary Table 9 sheet 1). Since
Ppp1r3 also affects somatic excitability, a second cluster with
29 members was formed around Ppp1r3c (Supplementary Table
9 sheet 2). A third functional cluster, built upon a significant
change (corrected) in MapK4 describes 53 genes related to
synaptogenesis (Supplementary Table 9 sheet 3). The fourth
cluster describes genes related to the fusion of vesicles and
is built upon a significant change (corrected) in Vps33B and
Ppp1r3c and contains 24 genes (Supplementary Table 9 sheet 4).
In line with their role in adjusting dendritic excitability, both
Ppp1r3 and Neto1 are involved in calcium influx to the MSNs.
Therefore, a separate cluster describing genes related to Calcium
metabolismwhich contains 25 genes was formed (Supplementary
Table 9 sheet 5). The sixth cluster containing 11 genes built
upon a significant change (corrected) in Abca1 describes genes
related to cholesterol and very long chain fatty acid metabolism
(Supplementary Table 9 sheet 6). The seventh cluster is based on
significant (corrected) change in Penk1 following STN-DBS in
both Drd1a and Drd2 expressing MSNs (Supplementary Table 9
sheet 7). This cluster is related to the changes in neuropeptides
and monoamines which serve a very broad range of functions.
The final and largest cluster containing 58 genes built upon a
significant change (corrected) in three genes (Ppp1r3c, Sorcs2,
and Gapdh) describes genes related to apoptosis (Supplementary
Table 9 sheet 8).
Further clusters were also generated by grouping functionally
related uncorrected genes only. Comprehensive lists of genes
involved in each major uncorrected function/cluster are given in
Supplementary Table 9 (sheets 9–20).
Validation of Findings
qRT-PCR was performed on five selected genes to verify the
microarray results. We chose four marker genes Drd1a, Drd2,
Pdyn, and Penk1 as well as Neto1 as a significantly altered
gene after STN-DBS. Results of the qRT-PCR are in accordance
with the microarray results. Thus, expression of Pdyn decreases
in Drd1a MSNs and expression of Penk1 increases in Drd2
MSNs while expression of Drd1a and Drd2 remain constant
following DBS. Moreover, STN-DBS leads to an increase in
level of Neto1 gene in Drd2MSNs but no change in Drd1a
MSNs.
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TABLE 1 | Fold changes of significantly altered genes (corrected) in either Drd2 or Drd1a expressing MSNs following STN-DBS and associated functional
clusters for functional analysis.
Functional cluster Significant gene P value Drd2 MSNs Drd1a MSNs
Fold change Fold change
(STN-DBS vs. sham) (STN-DBS vs. sham)
Dendritic excitability Ppp1r3c 2.17E-05 3.966 −2.008
Neto1 2.97E-05 −2.364 −1.049
Sorcs2 2.53E-07 −2.415 −1.038
Somatic excitability Ppp1r3c 2.17E-05 3.966 −2.008
Synaptogenesis MapK4 3.75E-05 −3.061 1
Fusion of vesicles Vps33B 4.84E-07 4.441 1.378
Ppp1r3c 2.17E-05 3.966 −2.008
Calcium metabolism Ppp1r3c 2.17E-05 3.966 −2.008
Neto1 2.97E-05 −2.364 −1.049
Cholesterol and VLCFA metabolism Abca1 9.15E-06 1.724 −1.067
Neuropeptides and monoamines Penk1 3.37E-05 −1.59 1.523
Apoptosis Gapdh 2.76E-05 −1.537 1.1273
Sorcs2 2.53E-07 −2.415 −1.038
Discussion
Our findings demonstrate that the most striking effects of STN-
DBS on striatal MSNs are exerted on the Drd2 expressing
population of the indirect pathway with only minor changes
apparent in Drd1a expressing MSNs of the direct pathway.
Thus, within the indirect pathway there are eight significantly
altered genes following STN-DBS. Of these eight genes, two
were also significantly altered in the direct pathway, but no
genes were significantly altered in exclusively in the direct
pathway. A complementary study may also investigate the
temporal changes in gene expression during the 14 days of nigro
striatal degeneration. The observed dominant involvement of
the indirect pathway is unsurprising as both the striatofugal and
subthalamofugal projections are highly collateralized systems. A
predominant involvement of the indirect vs. the direct pathway
may be explained by these collateralized systems. However,
it is established that corticosubthalamic axons are collaterals
of corticospinal axons which also send collaterals to MSNs
of the indirect pathway with only minor innervation of the
MSNs of the direct pathway (Reiner et al., 2010; Kita and
Kita, 2012). Furthermore, this finding supports the suggestion
that the antidromic activation of corticosubthalamic neurons is
involved in the therapeutic effect of STN-DBS (Li et al., 2007;
Hammond et al., 2008). It has been largely debated if STN-
DBS causes excitation or inhibition in STN and its downstream
targets in pallidum (Kopell et al., 2006; Montgomery and Gale,
2008). The major genetic changes we observe in the striatum are
not likely to be a result of long polysynaptic loops linking the
subthalamic nucleus to the striatum such as STN-GPi-Thalamo-
Cortico-Striatal circuit because each synapse is facilitated with
several mechanisms to dampen hyper- and hypo-excitation. Our
results however, show a pronounced over activity in striatum
which may be best described in the light of antidromic activity
of motor cortical neurons following STN-DBS. In concert, our
observations suggest that, by various mechanisms discussed
in details below, following STN-DBS the indirect pathway is
capable of receiving an enhanced input; however concurrent
alterations are also apparent that would dampen the output
of these Drd2 MSNs. The combined effects of STN-DBS on
MSNs of the indirect pathway are summarized in Figure 3.
Our discussion will focus on each of the cellular mechanisms
implicated in this imbalance between the input and output of
striatal MSNs.
Mechanisms of Enhanced Input
Enhanced Dendritic Excitability
Expression of Ppp1r3c is decreased 3.97 fold in Drd2 MSNs
post STN-DBS. Ppp1r3c is a regulatory subunit of protein
phosphatase-1 (PP1) which plays a key role in inhibition of
protein kinase A (PKA). PKA and PP1 compete to modulate
ion channels in opposing directions. Thus, while most cation
channels on MSN membranes (AMPA, NMDA, L-type Ca) are
upregulated by PKA and downregulated by PP1, most anion
channels (GABA) are downregulated by PKA and upregulated
by PP1. Two major exceptions are N/P-type calcium channels,
involved in release of vesicles from terminal boutons, and
fast voltage gated Na channels, involved in generation of
action potentials, both which are downregulated by PKA and
upregulated by PP1. Decreased expression of Ppp1r3c in the
indirect pathway following STN-DBS may therefore result in an
increased excitatory inflow to Drd2 MSNs via increased cationic
vs. anionic influx.
Neto1 is an auxiliary subunit of kainaite receptors (KARs)
purportedly responsible for the slow kinetics and high affinity
of GluK2 subunit of these receptors (Molnar, 2013) which is the
dominant subunit in the striatum. In addition to KARs, Neto1
is also associated with NMDARs via an intracellular domain
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FIGURE 3 | Alterations in cellular mechanisms in Drd2-expressing
striatopallidal MSNs following STN-DBS. STN-DBS changes the
expression of genes involved in spine formation and synaptogenesis.
These changes suggest that more spines and synapses may be formed
on Drd2 MSNs after stimulation. In addition, (A) Excitatory input to the
spines through kainate and NMDA receptors as well as L-Type Calcium
channels is enhanced and inhibitory input via GABA receptors is
suppressed so that the neuron may become more excitable on it dendritic
input. (B) Voltage gated Sodium channels and Sodium leak channels are
suppressed thus potentially rendering the neurons less prone to action
potential generation. (C) N/P type calcium channels are suppressed on
the axon terminals potentially hindering vesicular release. Axonal transport
machinery is suggested to be diminished in Drd2 MSNs accordingly. Other
changes observed in Drd2 MSNs suggest high stress induced in these
neurons due to STN-DBS. Such changes are related to Oxidative and ER
stress and abnormal lipid and cholesterol metabolism and apoptosis. Such
changes may be results of enhanced input and diminished output to these
neurons.
interaction with GluN2A and GluN2B subunits (Cousins et al.,
2013). Neto1 is reported to be required for proper delivery
and stability of NMDARs containing GluN2A subunit to the
postsynaptic density and knockout mice lacking this gene show
impaired spatial learning (Ng et al., 2009). Via its interaction
with KARs and NMDARs, Neto1 is located in an ideal location
to control the excitatory input to the MSN. Expression of this
gene increases in Drd2 MSNs 2.36 fold but remains stable in
Drd1a MSNs following STN-DBS. Thus, STN-DBS may enhance
the activity of KARs and NMDARs on Drd2 expressing MSNs,
a result that is in accordance with our suggestion that STN-DBS
increases dendritic excitation in the indirect pathway.
The hypothesis that STN-DBS modifies dendritic excitability
is further supported by uncorrected changes in 28 genes in Drd2
expressing MSNs and 13 Genes in Drd1a MSNs (Supplementary
Table 9 Sheet 1). Some of the altered genes directly code for ion
channels or their accessories, while others are modulators of ion
channels. A variety of protein kinases and phosphatases which
are known to modulate activity of voltage and ligand gated ions
channels on MSNs are also among the significantly altered genes.
Dendritic Spine Formation
Expression of Mapk4 (Erk4) increases 3.06 fold in Drd2 MSNs
but remains stable in Drd1a MSNs following STN-DBS. Erk4 is
preferentially expressed in the prefrontal cortex, olfactory bulb
and the striatum (Rousseau et al., 2010). Erk4, and paralogous
Erk3 (Mapk6), use MK5 as a substrate to affect gene expression
in cells and the Erk3-MK5 signaling complex has been shown
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to induce spine formation on hippocampal neurons (Brand
et al., 2012). Thus, Mapk4 may also be involved in the process
of dendritic spine formation in striatal MSNs. The increased
expression of Erk4 three in Drd2 MSNs following STN-DBS may
preferentially induce the formation of dendritic spines in Drd2
expressing MSNs leading to an enhanced ability to receive input
in these neurons.
In total, 40 genes involved in neurite outgrowth are altered in
Drd2 MSNs and 31 in Drd1a MSNs after STN-DBS suggesting
that dendritic morphology may be significantly altered after
STN-DBS. The neuron navigator gene Nav1 increases 2.58 fold
selectively in Drd1aMSNs after stimulation. Similarly, expression
levels of Rarb, encoding retinoic acid receptor beta, which has
been shown to induce spine formation (Chen and Napoli, 2008),
increases 3.24 fold selectively in Drd2 MSNs. Gene expression of
Cadherin 4, a calcium dependent regulator of neurite outgrowth
and synaptogenesis, increases 2.4 fold and 1.65 in Drd1a and
Drd2 MSNs respectively. Furthermore, there is a 2.99 fold
decrease in expression of Cspg5, a negative signal for neurite
growth, in Drd1a neurons after DBS with negligible (∼9%)
change in Drd2 MSNs. Expression of Baiap2, an insulin receptor
tyrosine kinase substrate known to regulate spine formation on
dendritic branches (Choi et al., 2005) and rac-mediated actin
cytoskeleton regulation (Connolly et al., 2005), decreases 2.09
fold in Drd1a MSNs and increases 1.79 fold in Drd2 MSNs.
This would have widespread implications for MSN function and
certainly warrants further study (Supplementary Table 9 Sheet 3).
Calcium Influx
Both Ppp1r3c and Neto1 are also implicated in calcium influx.
As stated above, PP1 inhibits the activity of L-Type calcium
channels while the involvement of Neto1 in NMDA receptor
activity modulates calcium influx. Furthermore, Neuronatin
(Nnat), a dendritically translated gene whose over expression
releases calcium from endoplasmic reticulum (Oyang et al., 2011)
increases 2.67 fold in Drd1a expressing MSNs after DBS. In total,
14 genes in Drd2 and six genes in Drd1a MSNs all involved in
regulation of calcium level in the MSNs are altered significantly
after STN-DBS. Altering the neuronal calcium concentration
can cause a myriad of effects, including influencing excitability,
vesicular release and, in excess, neurotoxicity. Indeed, several of
these genes implicated in calcium influx are also implicated in
apoptosis, as discussed below.
Mechanisms of Diminished Output
Reduced Somatic Excitability
Scn2a1, which encodes the alpha subunit of fast sodium channels,
is of particular interest in the present study as its pattern of
expression shifts from being dominant in the indirect pathway in
sham stimulated animals to being dominant in the direct pathway
following STN-DBS. Thus, following STN-DBS Scn2a1 increases
2.87 fold in Drd1a MSNs and decreases 2.21 fold in Drd2 MSNs.
Similarly, Nalcn which encodes sodium leak channels, decreases
2.46 fold in Drd2 MSNs and 3.35 fold in Drd1a MSNs following
STN-DBS. A reduction in sodium leak channels may lead to a
hyperpolarized resting potential such that excitatory postsynaptic
potentials (EPSPs) are less likely to generate action potentials.
Our results also show mixed patterns regarding expression
of voltage gated potassium channels following STN-DBS. While
expression of Kcnab1 increases 2.25 fold in Drd2 expressing
MSNs, expression of Kcna1 deceases 1.52 fold and increases 1.96
fold in Drd1a MSNs. These results indicate that the shape and
the refractory period of the action potential may be altered in
Drd1a and Drd2MSNs after STN-DBS. Future studies employing
electrophysiology would be required to elucidate potential
changes in action potential characteristics following STN-DBS.
Reduced Transport and Fusion of Vesicles
Vps33b is a Sec1/Munc18 like gene involved in trafficking of
vesicles and their engagement with the SNARE complex and
fusion (Gissen et al., 2005; Baker et al., 2013). Vps33b expression
decreases 4.44 fold in Drd2 MSNs and only 1.38 fold in Drd1a
MSNs post STN-DBS, suggesting that vesiclular trafficking and
release may be preferentially diminished in the indirect pathway.
Sixteen additional genes are also implicated in transport and
fusion of vesicles (Supplementary Table 9 sheet 4) and a further
17 genes involved in axonal cargo transport undergo significant
changes after STN-DBS (Supplementary Table 9 sheet 11). For
example expression of the kinesin superfamily member, Kif1b
is decreased 8.01 fold in Drd2 MSNs and increased 1.58 fold in
Drd1a MSNs after STN-DBS, suggesting a hindrance of axonal
transport in Drd2 MSNs.
Other Effects of STN-DBS
Long Term Plasticity
Several genes associated with long term plasticity are significantly
altered following STN-DBS. Sorcs2 is preferentially expressed
in the striatum and olfactory bulb and is believed to mediate
long term depression (LTD) by acting as a co-receptor for
proBDNF. BDNF promotes long term potentiation (LTP) via its
interaction with TrkB receptors while proBDNF promotes LTD
via interaction with a p75-Sorcs2 complex. Thus, the pro and
the mature forms of BDNF are suggested to compete with each
other providing means of bidirectional plasticity (Je et al., 2012).
Our results indicate that in Drd2 MSNs, Sorcs2 expression is 2.42
fold higher after STN-DBS. Thus, in Drd2 MSNs the competition
between LTP and LTD may tip toward LTD following STN-DBS.
Expression of Sorcs2 was unchanged in Drd1a MSNs following
STN-DBS. Interestingly it has been shown by others that 6-
OHDA lesioning of the nigrostriatal pathway leads to a selective
loss of dendritic spines in Drd2 expressing MSNs, yet remaining
Drd2 spines undergo LTP (Day et al., 2006). Our results suggest
that Drd2 but not Drd1a MSNs may tend to recover lost spines
but in turn Drd2MSN spines undergo LTD. Thus, STN-DBSmay
have the reverse effect of 6-OHDA lesioning reported by Day and
colleagues.
Cholesterol and Fatty Acid Metabolism
In total, eight Drd2 and five Drd1a MSN genes involved in
metabolism of cholesterol and fatty acids are significantly altered
after STN-DBS. Abca1 mediates the eﬄux of cholesterol and
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phospholipids to lipid-poor apolipoproteins (apo-A1 and apoE).
It has been shown that the expression of Abca1 is correlated
with intensity of dementia in Alzheimer’s patients (Akram et al.,
2010). Expression of the Abca1 gene decreases 1.72 fold in
Drd2 expressing MSNs but remains unchanged in Drd1a MSNs.
This suggests that cholesterol may not be efficiently removed
from MSNs of the indirect pathway after STN-DBS. Intracellular
cholesterol is known to promote synaptogenesis and axonal and
dendritic growth (Karasinska and Hayden, 2011). Thus, elevated
cholesterol levels in Drd2 expressing MSNs would facilitate the
formation of new spines, a process already highlighted by our
observed effects of STN-DBS on Mapk4 in Drd2 expressing
MSNs. It is important to note that Hdlbp, that encodes high
density lipoprotein binding protein and likely functions in the
removal of excess cellular cholesterol, decreases 3.12 fold in
Drd1a MSNs and increases 2.82 fold in Drd2 MSNs. This
observation may point to a compensatory mechanism within
Drd2 MSNs in reaction to elevated cholesterol. Further research
should elucidate the influence of STN-DBS on striatal cholesterol
metabolism.
There was a 5.42 fold decrease in Abcd2 in Drd1a MSNs
following STN-DBS. The peroxisomal ATP-binding cassette
transporter encoded by this gene is implicated in transport of
very long chain fatty acids into peroxisomes. Thus, reduced
expression of Abcd2 may suggest diminished fatty acid break
down in Drd1a MSNs. Other peroxisome related genes, Pex13
and Pex2 are significantly altered following STN-DBS. Pex2 is
decreased 2.44 fold in Drd1a MSNs and increased 1.83 fold in
Drd2 MSNs and Pex13 is increased 1.58 fold in Drd2 MSNs
after STN-DBS. As opposed to Abcd2, these two genes are not
transporters of very long chain fatty acids, instead they are
needed for biogenesis of proxisomes. Our data showing that
both synthesis of peroxisomes and transport of fatty acids into
them is diminished in Drd1a MSNs, suggest that fatty acid
accumulationmay occur in Drd1aMSNs after STN-DBS. In Drd2
MSNs our findings suggest an increased synthesis of peroxisomal
subunits which may be an effort to counteract the observed
diminished transport of very long chain fatty acids in Drd2
MSNs. Additionally, Pex genes have been reported to interfere
with alpha-synuclein aggregation so it remains possible that DBS
may alter further aggregation of alpha-synuclein in PD.
Build-up of very long chain fatty acids can interfere
with a variety of striatal signaling mechanisms including
endocannabinoid signaling (Lovinger and Mathur, 2012) and
diacylglycerol metabolism. The hypothesis that STN-DBS my
enhance diacylglycerol in striatal MSNs is further supported by
the observation that expression of Dgkq, a gene which encodes
a strong inhibitor of diacylglycerol (diacylglycerol kinase), is
altered following STN-DBS. Thus, this gene is expressed slightly
higher (27%) in Drd1a MSNs compared to Drd2 MSNs prior to
stimulation, but following STN-DBS this pattern is reversed such
that DGKQ is 2.7 fold higher in Drd2 MSNs than Drd1a MSNs.
Enkephalin and Immediate Early Genes
It has long been established that Enkephalin is co-expressed with
D2 receptors in Drd2 MSNs where it has been suggested to play
a regulatory role in expression of immediate early genes (IEGs).
Thus, enkephalin inhibits IEGs after they are induced following
D2 receptor blockade (Steiner and Gerfen, 1998). Furthermore,
expression of the proenkephalin gene, Penk1 increases following
6-OHDA lesions of the nigrostriatal pathway. Our results show
that expression of Penk1 also increases a modest 1.59 fold
in Drd2 expressing MSNs after STN-DBS, whereas enkephalin
convertase, Cpe, decreases 1.8 fold, which would be expected
to result in the inhibition of IEGs. The timing of extraction
of RNA in the present study precludes the analysis of IEGs,
however changes in IEGs would be unlikely to be implicated in
the long-term effects of STN-DBS.
Apoptosis
The largest cluster generated by our functional analysis implies
that apoptosis may be induced in Drd2 expressing MSNs post
STN-DBS. In total 43 uncorrected genes involved in apoptosis
were mapped onto the backbone of a significant increase in
Gapdh of 1.54 fold in Drd2 expressing MSNs (Supplementary
Table 9 Sheet 8). It has been suggested that Gapdh is involved in
apoptotic cascades in neurodegenerative diseases (Chuang et al.,
2005). Furthermore, Gapdh is implicated in the cytotoxicity of
both mutant Huntingtin (Bae et al., 2006) and Htt (Kaltenbach
et al., 2007). Moreover, two other corrected genes Ppp1r3c and
Sorcs2 are also implicated in apoptosis and a fourth corrected
gene, Nbn, implicated in apoptosis was shown to undergo a
subthreshold 1.48 fold change in Drd2 MSNs. A large increase
in the expression of Zeb2 in Drd1a MSNs (4.68 fold) and marked
decrease in Drd2 MSNs (3.43 fold) is also observed. This gene
is a repressor of the TGF beta pathway (Postigo, 2003) and
is suggested to inhibit apoptosis in neurons. Collectively these
data suggest that STN-DBS may selectively promote apoptosis
in Drd2 expressing MSNs. Moreover, Sepp1, which encodes a
selenium transport protein and considered as a primary line
of defense against oxidative stress, is decreased 4.34 fold in
Drd2 MSNs and increased 2.45 fold in Drd1a MSNs following
STN-DBS. This would render Drd2 expressing MSNs more
susceptible to oxidative stress following STN-DBS. Although
human studies have shown profound changes in cell death
pathways and in peripheral blood in PD in human and mouse
(Macchi et al., 2015), it is not straight forward to expand that
pathologic effect to current therapeutic effect. Future studies
looking at the number of viable striatal Drd2 expressing MSNs
should reveal the extent of this potentially damaging effect of
stimulation.
Conclusions
In conclusion, our data suggest that at the level of the striatum,
the influence of STN-DBS is predominantly exerted on the
projections neurons of the indirect pathway with only minimal
effect on the direct pathway. This is in contrast to changes
induced in striatal projection neurons following administration
of L-DOPA. Recent studies (Visanji et al., 2012; Heiman
et al., 2014) have shown that following L-DOPA administration
expression of many more genes change in Drd1a compared
to Drd2 MSNs. Interestingly, striatal genes whose expression
changes following L-DOPA administration (Visanji et al., 2012;
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Heiman et al., 2014) have a very slim overlap with the
striatal genes whose expression changes following STN-DBS
(only three Drd1a genes and three Drd2 genes). This may
suggest that mechanisms controlling therapeutic effect of STN-
DBS may be very different from those causing the pathology
of PD. The combined alterations in gene expression in the
indirect pathway on the one hand would lead to generation
of larger EPSPs, smaller IPSPs, increased dendritic spines
and higher calcium influx into the dendritic tree of these
neurons but at the same time processes are implicated that
would hamper the process of initiation of action potentials,
transport of neurotransmitters from soma to axon terminals
and vesicular release. Finally, changes in expression of several
genes suggest that apoptosis is promoted in Drd2 expressing
MSNs following DBS and that cholesterol and fatty acid
metabolism may also be affected by STN-DBS. This increased
understanding of the molecular mechanisms induced by STN-
DBS will hopefully initiate further investigation of novel targets
for future non-surgical therapies to reduce the motor symptoms
of PD.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fncel.
2015.00221/abstract
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